Atezolizumab (ATZ) is a humanized monoclonal antibody that is programmed to cell death-ligand 1 (PD-L1), which blocks the binding of PD-L1 to programmed cell death-1 (PD-1) and restores anti-cancer immunity [12]. Here, PDCD1 is linked to cancer.